{
    "clinical_study": {
        "@rank": "50402", 
        "arm_group": [
            {
                "arm_group_label": "Ramosetron 0.6mg", 
                "arm_group_type": "Experimental", 
                "description": "Ramosetron 0.6mg intravenous injection 30min before chemotherapy"
            }, 
            {
                "arm_group_label": "Ramosetron 0.45mg", 
                "arm_group_type": "Experimental", 
                "description": "Ramosetron 0.45mg intravenous injection 30min before chemotherapy"
            }, 
            {
                "arm_group_label": "Ramosetron 0.3mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Ramosetron 0.3mg intravenous injection 30 min before chemotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designted to know optimal dose of Ramosteron to control for chemotherapy\n      induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and\n      clinilcal parameters using Rhodes Index."
        }, 
        "brief_title": "Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Colon Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Colonic Neoplasms", 
                "Vomiting"
            ]
        }, 
        "detailed_description": {
            "textblock": "Nausea and vomiting is a common adverse event during chemotherapy treatment. Even if\n      preventive medicines such as dopamine receptor antagonist, corticosteroid, serotonin\n      receptor antagonist, has been developed and used, there is residual nausea and/or vomiting\n      in a significant percentage of patients treated for cancer. Serotonin receptor antagonist is\n      the most potent antiemetic agent and has been used widely. However, the optimal dose of\n      serotonin antagnosit based on individual symptoms is not defined. Therefore, this study was\n      conducted to design standardization model for optiomal serotonin antagonist concentration\n      using pharmacodynamic study and Rhodes Index as a suggogate marker for CINV."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who recevied moderate emetogenic chemotherapy\n\n          -  Age between 18-75\n\n          -  ECOG PS 0-2\n\n          -  Adequate organ fuction including bone marrow, liver and kidney\n\n        Exclusion Criteria:\n\n          -  Gastrointestinal obstruction or carcinomatosis peritonei\n\n          -  CNS metastasis or disability in CNS\n\n          -  Intractable medical illness\n\n          -  Pregnancy or inadequate contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02076529", 
            "org_study_id": "RamosetronPK"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ramosetron 0.3mg", 
                "intervention_name": "Ramosetron 0.3mg", 
                "intervention_type": "Drug", 
                "other_name": "Nasea 0.3mg"
            }, 
            {
                "arm_group_label": "Ramosetron 0.45mg", 
                "intervention_name": "Ramosetron 0.45mg", 
                "intervention_type": "Drug", 
                "other_name": "Nasea 0.45mg"
            }, 
            {
                "arm_group_label": "Ramosetron 0.6mg", 
                "intervention_name": "Ramosetron 0.6mg", 
                "intervention_type": "Drug", 
                "other_name": "Nasea 0.6mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ramosetron"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "chemotherapy induced nausea vomiting", 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Gwangju", 
                    "country": "Korea, Republic of", 
                    "state": "Jeollanamdo", 
                    "zip": "519-809"
                }, 
                "name": "Chonnam National University Hwasun Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Study About Pharmacokinetic and Pharmacodynamics of Ramosetron in Chemotherapy Induced Nausea and Vomiting", 
        "overall_official": {
            "affiliation": "CNUHH", 
            "last_name": "Sang-Hee Cho, M.D.Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Pharmacokinectics using NONMEM will be analyzed from serum after Ramosetron injection from 10 min to 48 hours (10min, 1hr, 6hr, 24hr, 48hr)", 
            "measure": "Pharmacokinetic profile of Ramosetron according to 3 level of dose", 
            "safety_issue": "No", 
            "time_frame": "10min to 48 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02076529"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chonnam National University Hospital", 
            "investigator_full_name": "Sang-Hee Cho", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Monitor using Rhodes Index will be performed each time at 1hour, 6hour, 24hour, 48hour and seven dyas after Ramosetron injection", 
            "measure": "Rhodes Index", 
            "safety_issue": "No", 
            "time_frame": "1 hour to seven days post-dose"
        }, 
        "source": "Chonnam National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chonnam National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}